Lantheus Medical Imaging, Inc.

153 articles about Lantheus Medical Imaging, Inc.

• Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent

  12/9/2020

  Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted the New Drug Application for PyLTM, a prostate specific membrane antigen -targeted positron emission tomography imaging agent for prostate cancer.

• CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences

  11/9/2020

  Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced that management will present at two investor conferences in November.

• Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference

  9/3/2020

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the Wells Fargo 2020 Virtual Healthcare Confe

• Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®

  8/12/2020

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced the U.S. Food and Drug Admi

• Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results

  7/30/2020

  Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portfolio of oncology therapeutics and diagnostics to pipeline

• Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time

  7/23/2020

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 30, 2020, to discuss its financial and operating results for the second quarter of 2020.

• Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting

  7/1/2020

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that 17 abstracts highlighting PyL™ (18F-DCFPyL) have been selected for presentation at the virtual Society of Nuclear Medicine and Molecular Imaging

• Lantheus Completes Merger with Progenics

  6/22/2020

  Lantheus Holdings, Inc. announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer.

• Lantheus Holdings to Present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference

  6/16/2020

  To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

• Lantheus Stockholders Approve Share Issuance For Merger with Progenics

  6/16/2020

  Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), announced that at a special meeting held earlier today, Lantheus’ stockholders voted to approve the issuance of common stock related to the Company’s proposed merger with Progenics Pharmaceuticals, Inc. (

• Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference

  5/20/2020

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET on Wednesday, June 3.

• Lantheus Holdings to Present at the UBS Virtual Global Healthcare Conference

  5/5/2020

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference at 3:00 p.m. ET on Tuesday, May 19.

• Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results

  4/30/2020

  Worldwide revenue of $90.7 million for the first quarter 2020, representing an increase of 4.8% over the prior year period

• Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time

  4/16/2020

  Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time

• 

  Genetown Hotbed: Churning Along During the COVID-19 Pandemic

  3/31/2020

  As the biopharma industry responds to the COVID-19 pandemic, some of the area's companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here's a look.

• Lantheus Holdings to Present at the 31st Annual Piper Jaffray Healthcare Conference

  11/21/2019

  Lantheus Holdings, Inc. announced Mary Anne Heino, President and Chief Executive Officer, will participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference at 9:30 a.m. ET on Thursday, December 5 in New York.

• Velan Responds to Misleading Communications from Progenics

  10/23/2019

  Progenics Has Again Resorted to False Information and Misleading Innuendo in Seemingly Desperate Attempt to Avoid Accountability and Deprive Stockholders of Chance to Realize Company’s Full Value

• Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

  10/2/2019

  Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics

• Lantheus Holdings, Inc. Reports Second Quarter 2019 Financial Results

  7/25/2019

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its second quarter ended June 30, 2019.

• Lantheus Holdings to Host Second Quarter 2019 Earnings Conference Call on July 25, 2019 at 8:00 a.m. Eastern Time

  7/11/2019

  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 25, 2019, to discuss its financial and operating results for the second quarter of 2019.